Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 23, 2023Clinical and Experimental OphthalmologyOpen Access

Twenty‐four‐month real‐life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMatteo AiraldiUniversity of LiverpoolAIAlessandro InvernizziThe University of SydneyVNVuong NguyenUniversity of British Columbia

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Airaldi et al. (2023) studied this question.

synapsesocial.com/papers/6a9defe03472a2bf021057a8https://doi.org/10.1111/ceo.14305
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data2019 · 832 citations
  2. 2Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study2018 · 277 citations
  3. 3Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors2018 · 272 citations
  4. 4PREVALENCE OF POLYPOIDAL CHOROIDAL VASCULOPATHY IN WHITE PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION2017 · 73 citations
  5. 5Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration2016 · 115 citations